Chronic administration of risperidone in a rat model of schizophrenia: A behavioural, morphological and molecular study

Behavioural Brain Research

Volumn 242, Issue 1, 2013, Pages 178-190

  Castellano, O ^a,b   Arji, M ^a   Sancho, C ^a,b   Carro, J ^a,b   Riolobos, A S ^a,b   Molina, V ^a,b,c   Gomez Nieto R ^a,b   de Anchieta de Castro e Horta, José ^d   Herrero Turrion M J ^a,b   Lopez D E ^a,b  

^a UNIVERSITY OF SALAMANCA   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

^c UNIVERSITY OF VALLADOLID   (Spain)

^d SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

Author keywords

5 HT receptor; Antipsychotic drugs; Behaviour; DA receptor; Immunohistochemistry; Prefrontal cortex; Risperidone; Schizophrenia

Indexed keywords

CALBINDIN; DOPAMINE 2 RECEPTOR; GLIAL FIBRILLARY ACIDIC PROTEIN; IBOTENIC ACID; PARVALBUMIN; PROTEIN C FOS; RISPERIDONE; SEROTONIN 2A RECEPTOR;

ADULT ANIMAL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DAMAGE; CELL COUNT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORTICAL THICKNESS (BRAIN); DISEASE MODEL; GENE EXPRESSION; HIPPOCAMPUS; IMMUNOREACTIVITY; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

AGE FACTORS; ANIMALS; ANIMALS, NEWBORN; ANTIPSYCHOTIC AGENTS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; BRAIN; CELL COUNT; CREB-BINDING PROTEIN; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; EXCITATORY AMINO ACID AGONISTS; EXPLORATORY BEHAVIOR; FEMALE; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; GROOMING; HIPPOCAMPUS; IBOTENIC ACID; MALE; PARVALBUMINS; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA;

EID: 84872578236     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2012.12.036     Document Type: Article

References (118)

1. Weinberger D.R. Schizophrenia as a neurodevelopmental disorder. Schizophrenia 1995, 293-323. Blackwell Science Ltd., Cambridge. S.R. Hirsch, D.R. Weinberger (Eds.).
2. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 2005, 10:79-104.
3. Scherk H., Falkai P. Effects of antipsychotics on brain structure. Current Opinion in Psychiatry 2006, 19(2):145-150.
4. Wood G.K., Lipska B.K., Weinberger D.R. Behavioral changes in rats with early ventral hippocampal damage vary with age at damage. Brain Research. Developmental Brain Research 1997, 101:17-25.
5. Lipska B.K., Jaskiw G.E., Weinberger D.R. Postpubertal emergence of hyperresponsiveness to stress and to amphetamine after neonatal excitotoxic hippocampal damage: a potential animal model of schizophrenia. Neuropsychopharmacology 1993, 9(1):67-75.
6. Lipska B.K., Weinberger D.R. To model a psychiatric disorder in animals: schizophrenia as a reality test. Neuropsychopharmacology 2000, 23:223-239.
7. Lipska B.K. Using animal models to test a neurodevelopmental hypothesis of schizophrenia. Journal of Psychiatry and Neuroscience 2004, 29:282-286.
8. Sams-Dodd F., Lipska B.K., Weinberger D.R. Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood. Psychopharmacology 1997, 132:303-310.
9. Keith S. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness. Expert Review of Neurotherapeutics 2009, 9(1):9-31.
10. Newton S.S., Duman R.S. Neurogenic actions of atypical antipsychotic drugs and therapeutic implications. CNS Drugs 2007, 21(9):715-725.
11. Castellano O., Moscoso A., Riolobos A.S., Carro J., Arji M., Molina V., Lopez D.E., Sancho C. Chronic administration of risperidone to healthy rats: a behavioural and morphological study. Behavioural Brain Research 2009, 205:488-498.
12. Molina V., Gispert J.D., Reig S., Sanz J., Pascau J., Santos A., Desco M., Palomo T. Cerebral metabolic changes induced by clozapine in schizophrenia and related to clinical improvement. Psychopharmacology 2005, 178(1):17-26.
13. Paxinos G., Watson C. The rat brain in stereotaxic coordinates: the new coronal set-161 diagrams 2005, Academic Press, San Diego.
14. Zhang G., Terry A.V., Bartlett M.G. Sensitive liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences 2007, 15858(1-2):276-281.
15. Stanford S.C. The Open Field Test: reinventing the wheel. Journal of Psychopharmacology 2007, 21(2):134-135.
16. Wadenberg M.G., Browning J.L., Young K.A., Hicks P.B. Antagonism at 5-HT(2A) receptors potentiates the effect of haloperidol in a conditioned avoidance response task in rats. Pharmacology Biochemistry and Behavior 2001 Mar, 68(3):363-370.
17. Gundersen H.J., Bagger P., Bendtsen T.F., Evans S.M., Korbo L., Marcussen N., Møller A., Nielsen K., Nyengaard J.R., Pakkenberg B., et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. Acta Pathologica, Microbiologica et Immunologica Scandinavica 1988, 96(10):857-881.
18. Schmittgen T.D., Livak K.J. Analyzing real-time PCR data by the comparative C(T) method. Nature Protocols 2008, 3(6):1101-1108.
19. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
20. Roberts R.C., Force M., Kung L. Dopaminergic synapses in the matrix of the ventrolateral striatum after chronic haloperdol treatment. Synapse 2002, 45:78-85.
21. Roberts R.C., Lapidus B. Ultrastructural correlates of haloperidol-induced oral dyskinesias in rats: a study of unlabeled and enkephalin-labeled striatal terminals. Journal of Neural Transmission 2003, 110(9):961-975.
22. Kelley J.J., Roberts R.C. Effects of haloperidol on cholinergic striatal interneurons: relationship to oral dyskinesias. Journal of Neural Transmission 2004, 111(8):1075-1091.
23. Harvey P.D., Green M.F., Keefe R.S., Velligan D.I. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. Journal of Clinical Psychiatry 2004, 65(3):361-372.
24. Honey G.D., Bullmore E.T., Soni W., Varatheesan M., Williams S.C., Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America 1999, 96(23):13432-13437.
25. 1A receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Research 2000, 858(2):252-263.
26. Ichikawa J., Ishii H., Bonaccorso S., Fowler W.L., O'Laughlin I.A., Meltzer H.Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. Journal of Neurochemistry 2001, 76(5):1521-1531.
27. Terry A.V., Gearhart D.A., Warner S.E., Zhang G., Bartlett M.G., Middlemore M.L., Beck W.D., Mahadik S.P., Waller J.L. Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance. Neuroscience 2007, 146(3):1316-1332.
28. Terry A.V., Gearhart D.A., Mahadik S.P., Warsi S., Davis L.W., Waller J.L. Chronic exposure to typical or atypical antipsychotics in rodents: temporal effects on central α7 nicotinic acetylcholine receptors. Neuroscience 2005, 136:519-529.
29. Zhang M., Ballard M.E., Kohlhaas K.L., Browman K.E., Jongen-Rêlo A.L., van Unger L.V., Fox G.B., Gross G., Decker M.W., Dresher K.U., Rueter L.E. Effect of dopamine D3 antagonists on PPI in DBA/2J mice or PPI deficits induced by neonatal ventral hippocampal lesions in rats. Neuropsychopharmacology 2006, 31:1382-1392.
30. Barth V.N., Chernet E., Martin L.J., Need A.B., Rash K.S., Morin M., Phebus L.A. Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeledraclopride tracer. Life Sciences 2006, 78(26):3007-3012.
31. Aichhorn W., Weiss U., Marksteiner J., Kemmler G., Walch T., Zernig G., Stelzig-Schoeler R., Stuppaeck C., Geretsegger C. Influence of age and gender on risperidone plasma concentrations. Journal of Psychopharmacology 2005, 19(4):395-401.
32. Silva-Gomez A.B., Bermudez M., Quirion R., Srivastava L.K., Picazo O., Flores G. Comparative behavioural changes between male and female postpubertal rats following neonatal excitotoxic lesions of the ventral hippocampus. Brain Research 2003, 973:285-292.
33. Beninger R.J., Tuerke K.J., Forsyth J.K., Giles A., Xue L., Boegman R.J., Jhamandas K. Neonatal ventral hippocampal lesions in male and female rats: effects on water maze, locomotor activity, plus-maze and prefrontal cortical GABA and glutamate release in adulthood. Behavioural Brain Research 2009, 202(2):198-209.
34. A receptor expression in neonatal ventral hippocampal lesioned rats: comparison of prepubertal and postpubertal periods. Synapse 2007, 61:357-366.
35. Berg S.A., Chambers R.A. Accentuated behavioral sensitization to nicotine in the neonatal ventral hippocampal lesion model of schizophrenia. Neuropharmacology 2008, 54(8):1201-1207.
36. Alquicer G., Silva-Gomez A.B., Peralta F., Flores G. Neonatal ventral hippocampus lesion alters the dopamine content in the limbic regions in postpubertal rats. International Journal of Developmental Neuroscience 2004, 22:103-111.
37. Alquicer G., Morales-Medina J.C., Quirion R., Flores G. Postweaning social isolation enhances morphological changes in the neonatal ventral hippocampal lesion rat model of psychosis. Journal of Chemical Neuroanatomy 2008, 35:179-187.
38. Tseng K.Y., O'Donnell P. Post-pubertal emergence of prefrontal cortical up states induced by D1-NMDA co-activation. Cerebral Cortex 2005, 15(1):49-57.
39. Tseng K.Y., O'Donnell P Dopamine modulation of prefrontal cortical interneurons changes during adolescence. Cerebral Cortex 2007, 17(5 (May)):1235-1240.
40. Abdul-Monim Z., Reynolds G.P., Neill J.C. The effect of atypical and classical antipsychotics on sub chronic PCP-induced cognitive deficits in a reversal-learning paradigm. Behavioural Brain Research 2007, 169(2):263-273.
41. Rueter L.E., Ballard M.E., Gallagher K.B., Basso A.M., Curzon P., Kohlhaas K.L. Chronic low dose risperidone and clozapine alleviate positive but not negative symptoms in the rat neonatal ventral hippocampal lesion model of schizophrenia. Psychopharmacology 2004, 176:312-319.
42. Richtand N.M., Taylor B., Welge J.A., Ahlbrand R., Ostrander M.M., Burr J., Hayes S., Coolen L.M., Pritchard L.M., Logue A., Herman J.P., McNamara R.K. Risperidone treatment prevents elevated locomotor activity following neonatal hippocampal lesions. Neuropsychopharmacology 2006, 31:77-89.
43. Karl T., Duffy L., O'brien E., Matsumoto I., Dedova I. Behavioural effects of chronic haloperidol and risperidone treatment in rats. Behavioural Brain Research 2006, 171(2):286-294.
44. Drago F., Contarino A., Marino R., Anzallo C., Valerio C., Rampello L., Raffaele R., Scapagnini U. Effects of acute or chronic administration of risperidone on motor and sexual behavior of male rats. Pharmacological Research 1997, 35(1):17-25.
45. Rebec G.V., Christensen J.R., Guerra C., Bardo M.T. Regional and temporal differences in real-time dopamine efflux in the nucleus accumbens during free-choice novelty. Brain Research 1997, 776:61-67.
46. Rebec G.V., Grabner C.P., Johnson M., Pierce R.C., Bardo M.T. Transient increases in catecholaminergic activity in medial prefrontal cortex and nucleus accumbens shell during novelty. Neuroscience 1997, 76:707-714.
47. Schroeder U., Schroeder H., Schwegler H., Sabel B.A. Neuroleptics ameliorate phencyclidine-induced impairments of short-term memory. British Journal of Pharmacology 2000, 130(1):33-40.
48. Rebec G.V. Dopamine, glutamate, and behavioral correlates of striatal neuronal activity. Advances in Pharmacology 1998, 42:737-740.
49. Chambers R.A., Moore J., McEvoy J.P., Levin E.D. Cognitive effects of neonatal hippocampal lesions in a rat model of schizophrenia. Neuropsychopharmacology 1996, 15:587-594.
50. Nicolaou N.M., Garcia-Munoz M., Arbuthnott G.W., Eccleston D. Interactions between serotonergic and dopaminergic systems in rat brain demonstrated by small unilateral lesions of the raphe nuclei. European Journal of Pharmacology 1979, 57:295-305.
51. Flores G., Alquicer G., Silva-Gomez A.B., Stewart J., Quirion R., Srivastava L.K. Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats alter neonatal excitotoxic lesions of the ventral hippocampus. Neuroscience 2005, 133:463-470.
52. Le Pen G., Grottick A.J., Higgins G.A., Martin J.R., Jenck F., Moreau J.L. Spatial and associative learning deficits induced by neonatal excitotoxic hippocampal damage in rats: further evaluation of an animal model of schizophrenia. Behavioural Pharmacology 2000, 11:257-268.
53. Chambers R.A., Self D.W. Motivational responses to natural and drug rewards in rats with neonatal ventral hippocampal lesions: an animal model of dual diagnosis schizophrenia. Neuropsychopharmacology 2002, 27:889-905.
54. Sharma T., Mockler D. The cognitive efficacy of atypical antipsychotics in schizophrenia. Journal of Clinical Psychopharmacology 1998, 18(2 (Suppl. 1)):12S-19S. [review].
55. Addy N., Levin E.D. Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology 2002, 27(4):534-541.
56. Wolff M.C., Leander J.D. Comparison of the effects of antipsychotics on a delayed radial maze task in the rat. Psychopharmacology 2003, 168(4):410-416.
57. Schotte A., Janssen P.F., Gommeren W., Luyten W.H., Van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology 1996, 124(1-2):57-73.
58. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sciences 2000, 68(1):29-39.
59. Sánchez-Santed F., de Bruin J.P., Heinsbroek R.P., Verwer R.W. Spatial delayed alternation of rats in a T-maze: effects of neurotoxic lesions of the medial prefrontal cortex and of T-maze rotations. Behavioural Brain Research 1997, 84(1-2):73-79.
60. Bardgett M.E., Baum K.T., O'Connell S.M., Lee N.M., Hon J.C. Effects of risperidone on locomotor activity and spatial memory in rats with hippocampal damage. Neuropharmacology 2006, 51(7-8):1156-1162.
61. Ninan I., Jardemark K.E., Wang R.Y. Olanzapine and clozapine but not haloperidol reverse subchronic phencyclidine-induced functional hyperactivity of N-methyl-d-aspartate receptors in pyramidal cells of the rat medial prefrontal cortex. Neuropharmacology 2003, 44(4):462-472.
62. Buckland P.R., D'Souza U., Maher N.A., McGuffin P. The effects of antipsychotic drugs on the mRNA levels of serotonin 5HT 2A and 5HT 2C receptors. Molecular Brain Research 1997, 48:45-52.
63. Kasper S., Resinger E. Cognitive effects and antipsychotic treatment. Psychoneuroendocrinology 2003, 28(Suppl. 1):27-38.
64. Bartzokis G., Lu P.H., Nuechterlein K.H., Gitlin M., Doi C., Edwards N., Lieu C., Altshuler L.L., Mintz J. Differential effects of typical and atypical antipsychotics on brain myelination in schizophrenia. Schizophrenia Research 2007, 93(1-3):13-22.
65. Benes F.M., Berretta S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 2001, 25(1):1-27.
66. Bernstein H.G., Grecksch G., Becker A., Höllt V., Bogerts B. Cellular changes in rat brain areas associated with neonatal hippocampal damage. Neuroreport 1999, 10(11):2307-2311.
67. Becker A., Grecksch G., Bernstein H.G., Höllt V., Bogerts B. Social behaviour in rats lesioned with ibotenic acid in the hippocampus: quantitative and qualitative analysis. Psychopharmacology 1999, 144(4):333-338.
68. Brisch R., Bernstein H.G., Krell D., Dobrowolny H., Bielau H., Steiner J., Gos T., Funke S., Stauch R., Knüppel S., Bogerts B. Dopamine-glutamate abnormalities in the frontal cortex associated with the catechol-O-methyltransferase (COMT) in schizophrenia. Brain Research 2009, 1269:166-175.
69. Piontkewitz Y., Arad M., Weiner I. Risperidone administered during asymptomatic period of adolescence prevents the emergence of brain structural pathology and behavioral abnormalities in an animal model of schizophrenia. Schizophrenia Bulletin 2011, 37(6):1257-1269.
70. Bernstein H.G., Smalla K.H., Dürrschmidt D., Keilhoff G., Dobrowolny H., Steiner J., Schmitt A., Kreutz M.R., Bogerts B. Increased density of prohibitin-immunoreactive oligodendrocytes in the dorsolateral prefrontal white matter of subjects with schizophrenia suggests extraneuronal roles for the protein in the disease. Neuromolecular Medicine 2012, (June). [epub ahead of print].
71. Rajkowska G., Miguel-Hidalgo J.J., Makkos Z., Meltzer H., Overholser J., Stockmeier C. Layer-specific reductions in GFAP-reactive astroglia in the dorsolateral prefrontal cortex in schizophrenia. Schizophrenia Research 2002, 57(2-3):127-138.
72. Toro C.T., Hallak J.E., Dunham J.S., Deakin J.F. Glial fibrillary acidic protein and glutamine synthetase in subregions of prefrontal cortex in schizophrenia and mood disorder. Neuroscience Letters 2006, 404(3):276-281.
73. Steffek A.E., McCullumsmith R.E., Haroutunian V., Meador-Woodruff J.H. Cortical expression of glial fibrillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophrenia Research 2008, 103(1-3):71-82.
74. Fatemi S.H., Folsom T.D., Reutiman T.J., Pandian T., Braun N.N., Haug K. Chronicpsychotropic drug treatment causes differential expression of connexin 43 and GFAP in frontal cortex of rats. Schizophrenia Research 2008, 104(1-3):127-134.
75. Webster M.J., Knable M.B., Johnston-Wilson N., Nagata K., Inagaki M., Yolken R.H. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. Brain, Behavior, and Immunity 2001, 15(4):388-400.
76. Webster M.J., O'Grady J., Kleinman J.E., Weickert C.S. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005, 133(2):453-461.
77. Toro C.T., Deakin J.F. Adult neurogenesis and schizophrenia: a window on abnormal early brain development?. Schizophrenia Research 2007, 90(1-3):1-14.
78. Selemon L.D., Lidow M.S., Goldman-Rakic P.S. Increased volume and glial density in primate prefrontal cortex associated with chronic antipsychotic drug exposure. Biological Psychiatry 1999, 46(2):161-172.
79. Lidow M.S., Elsworth J.D., Goldman-Rakic P.S. Down-regulation of the D1 and D5 dopamine receptors in the primate prefrontal cortex by chronic treatment with antipsychotic drugs. Journal of Pharmacology and Experimental Therapeutics 1997, 281(1 (April)):597-603.
80. Lipska B.K., Lerman D.N., Khaing Z.Z., Weickert C.S., Weinberger D.R. Gene expression in dopamine and GABA systems in an animal model of schizophrenia: effects of antipsychotic drugs. European Journal of Neuroscience 2003, 18:391-402.
81. Wong A.H., Lipska B.K., Likhodi O., Boffa E., Weinberger D.R., Kennedy J.L., Van Tol H.H. Cortical gene expression in the neonatal ventral-hippocampal lesion rat model. Schizophrenia Research 2005, 77:261-267.
82. Pellerin L., Magistretti P.J. Excitatory amino acids stimulate aerobic glycolysis in astrocytes via an activation of the Na+/K+ ATPase. Developmental Neuroscience 1996, 18(5-6):336-342.
83. Rothstein J.D., Martin L., Levey A.I., Dykes-Hoberg M., Jin L., Wu D., Nash N., Kuncl R.W. Localization of neuronal and glial glutamate transporters. Neuron 1994, 13(3):713-725.
84. Fatemi S.H., Laurence J.A., Araghi-Niknam M., Stary J.M., Schulz S.C., Lee S., Gottesman I.I. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophrenia Research 2004, 69(2-3):317-323.
85. Artigas F. The prefrontal cortex: a target for antipsychotic drugs. Acta Psychiatrica Scandinavica 2010, 121:11-21.
86. López-Gil X., Artigas F., Adell A. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. Current Pharmaceutical Design 2010, 16(5):502-515.
87. Tseng K.Y., Amin F., Lewis B.L., O'Donnell P. Altered prefrontal cortical metabolic response to mesocortical activation in adult animals with a neonatal ventral hippocampal lesion. Biological Psychiatry 2006, 60(6):585-590.
88. Tseng K.Y., O'Donnell P. D2 dopamine receptors recruit a GABA component for their attenuation of excitatory synaptic transmission in the adult rat prefrontal cortex. Synapse 2007, 61(10):843-850.
89. Goto Y., O'Donnell P. Prefrontal lesion reverses abnormal meso accumbens response in an animal model of schizophrenia. Biological Psychiatry 2004, 55:172-176.
90. Lewis D.A., Hashimoto T., Volk D.W. Cortical inhibitory neurons and schizophrenia. Nature Reviews Neuroscience 2005, 6(4):312-324.
91. Flores G., Barbeau D., Quirion R., Srivastava L.K. Decreased binding of dopamine D3 receptors in limbic subregions after neonatal bilateral lesion of rat hippocampus. Journal of Neuroscience 1996, 16:2020-2026.
92. Tseng K.Y., Lewis B.L., Hashimoto T., Sesack S.R., Kloc M., Lewis D.A., O'Donnell P. A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons. Journal of Neuroscience 2008, 28(48):12691-12699.
93. Zuo D.Y., Cao Y., Zhang L., Wang H.F., Wu Y.L. Effects of acute and chronic administration of MK-801 on c-Fos protein expression in mice brain regions implicated in schizophrenia with or without clozapine. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2009, 33(2):290-295.
94. Murphy C.A., Feldon J. Interactions between environmental stimulation and antipsychotic drug effects on forebrain c-fos activation. Neuroscience 2001, 104(3):717-730.
95. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2006, 31(9):1854-1863.
96. Wang H.D., Dunnavant F.D., Jarman T., Deutch A.Y. Effects of antipsychotic drugs on neurogenesis in the forebrain of the adult rat. Neuropsychopharmacology 2004, 29(7 (July)):1230-1238.
97. Wang H.D., Deutch A.Y. Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment. Neuropsychopharmacology 2008, 33(6 (May)):1276-1286.
98. O'Donnell P., Lewis B.L., Weinberger D.R., Lipska B.K. Neonatal hippocampal damage alters electrophysiological properties of prefrontal cortical neurons in adult rats. Cerebral Cortex 2002, 12:975-982.
99. Willner P. The dopamine hypothesis of schizophrenia: current status, future prospects. International Clinical Psychopharmacology 1997, 12(6):297-308.
100. Tallerico T., Novak G., Liu I.S., Ulpian C., Seeman P. Schizophrenia: elevated mRNA for dopamine D2(Longer) receptors in frontal cortex. Brain Research. Molecular Brain Research 2001, 87(2):160-165.
101. Kessler R.M., Woodward N.D., Riccardi P., Li R., Ansari M.S., Anderson S., Dawant B., Zald D., Meltzer H.Y. Dopamine D2 receptor levels in striatum, thalamus, substantia nigra, limbic regions, and cortex in schizophrenic subjects. Biological Psychiatry 2009, 65(12 (June)):1024-1031.
102. Bortolozzi A., Masana M., Díaz-Mataix L., Cortés R., Scorza M.C., Gingrich J.A., Toth M., Artigas F. Dopamine release induced by atypical antipsychotics in prefrontal cortex requires 5-HT(1A) receptors but not 5-HT(2A) receptors. International Journal of Neuropharmacology 2010, 13(10 (November)):1299-1314.
103. Leysen J.E., Janssen P.M., Schotte A., Luyten W.H., Megens A.A. Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors. Psychopharmacology 1993, 112(Suppl. 1):S40-S54.
104. Kusumi I., Takahashi Y., Suzuki K., Kameda K., Koyama T. Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. Journal of Neural Transmission 2000, 107:295-302.
105. Cartmell J., Perry K.W., Salhoff C.R., Monn J.A., Schoepp D.D. Acute increases in monoamine release in the rat prefrontal cortex by them Glu2/3 agonist LY379268 are similar in profile to risperidone, not locally mediated, and can be elicited in the presence of uptake blockade. Neuropharmacology 2001, 40(7):847-855.
106. Hertel P., Lindblom N., Nomikos G.G., Svensson T.H. Modulation of central serotonergic neurotransmission by risperidone: underlying mechanism(s) and significance of action. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1998, 22(5):815-834.
107. Ichikawa J., Kuroki T., Dai J., Meltzer H.Y. Effect of antipsychotic drugs on extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens. European Journal of Pharmacology 1998, 351(2):163-171.
108. Xia Z., Hufeisen S.J., Gray J.A., Roth B.L. The PDZ-binding domain is essential for the dendritic targeting of 5-HT2A serotonin receptors in cortical pyramidal neurons in vitro. Neuroscience 2003, 122(4):907-920.
109. Ichikawa J., Li Z., Dai J., Meltzer H.Y. Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism. Brain Research 2002, 956(2):349-357.
110. Catafau A.M., Corripio I., Pérez V., Martin J.C., Schotte A., Carrió I., Alvarez E. Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response. Psychiatry Research: Neuroimaging 2006, 148:175-183.
111. Tomelleri L., Jogia J., Perlini C., Bellani M., Ferro A., Rambaldelli G., Tansella M., Frangou S., Brambilla P. Neuroimaging network of the ECNP networks initiative. Brain structural changes associated with chronicity and antipsychotic treatment in schizophrenia. European Neuropsychopharmacology 2009, 19(12):835-840.
112. Broening H.W., Morford L.L., Vorhees C.V. Interactions of dopamine D1 and D2 receptor antagonists with D-methamphetamine-induced hyperthermia and striatal dopamine and serotonin reductions. Synapse 2005, 56(2):84-93.
113. Carey R.J., DePalma G., Damianopoulos E., Shanahan A., Müller C.P., Huston J.P. Pharmacological inhibition of DA- and 5-HT activity blocks spontaneous and cocaine-activated behavior: reversal by chronic cocaine treatment. Brain Research 2005, 1047(2):194-204.
114. Alex K.D., Yavanian G.J., McFarlane H.G., Pluto C.P., Pehek E.A. Modulation of dopamine release by striatal 5-HT2C receptors. Synapse 2005, 55(4):242-251.
115. Harvey J.A. Role of the serotonin 5-HT (2A) receptor in learning. Learning and Memory 2003, 10(5):355-362. [review].
116. Wood G.K., Quirion R., Srivastava L.K. Early environment contributes to developmental disruption of MPFC after neonatal ventral hippocampal lesions in rats. Synapse 2003, 50:223-232.
117. Breier A. Serotonin, schizophrenia and antipsychotic drug action. Schizophrenia Research 1995, 14(3):187-202.
118. Abi-Dargham A. Alterations of serotonin transmission in schizophrenia. International Review of Neurobiology 2007, 78:133-164.